Clinical trial · Observational
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
A Multi-centre Chart Review Study on the Treatment Patterns and Outcomes of Stage I-III Non-Small Cell Lung Cancer in China
NCT07316062CI-TRIAL-00121711MAPrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 12, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260912-000001
Summary
Brief summary (as posted)
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small-Cell Lung | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Treatment Patterns
- timeFrame
- Up to 50 months
- description
- Proportion of patients with different treatment regimens
- measure
- Proportion of unresected patients in SI/II/III
- timeFrame
- Up to 50 months
- description
- Proportion of patients who are unresected among SI/II/III NSCLC patients enrolled, respectively
- measure
- CRT rate in USIII
- timeFrame
- Up to 50 months
- description
- Proportion of patients who have CRT regimen among unresected SIII patients enrolled
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Stage I-III at initial NSCLC diagnosis * Aged ≥18 years at first diagnosis of NSCLC * Timeframe of NSCLC diagnosis: For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027 Exclusion Criteria: * NSCLC is not the primary cancer diagnosis * Patients with a recent history of other tumor or concurrent other tumor * Patients participating in interventional clinical trials at time of initial diagnosis * Patients with positive pregnancy status at the time of diagnosis
References
Publications (0)
Data not yet available
No reference posted for this study.